دورية أكاديمية
أعرض في EDS

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.

التفاصيل البيبلوغرافية
العنوان: Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.
المؤلفون: Deodhar A; 1Oregon Health and Science University, Portland, OR USA., Strand V; Biopharmaceutical Consultant, Portola Valley, CA USA., Conaghan PG; 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK., Sullivan E; Adelphi Real World, Bollington, UK., Blackburn S; Adelphi Real World, Bollington, UK., Tian H; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ USA., Gandhi K; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ USA., Jugl SM; 6Novartis Pharma AG, Basel, Switzerland., Alten R; 7Schlosspark-Klinik, University Medicine, Berlin, Germany.
المصدر: BMC rheumatology [BMC Rheumatol] 2020 Mar 02; Vol. 4, pp. 19. Date of Electronic Publication: 2020 Mar 02 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101738571 Publication Model: eCollection Cited Medium: Internet ISSN: 2520-1026 (Electronic) Linking ISSN: 25201026 NLM ISO Abbreviation: BMC Rheumatol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central Ltd., [2017]-
مستخلص: Background: Symptoms and comorbidities of ankylosing spondylitis (AS) considerably reduce health-related quality of life (HRQoL) and ability to work. This real-world study assessed rates of tumour necrosis factor inhibitor (TNFi) use and switching, treatment failure, and associations between failing TNFi and HRQoL, work productivity and activity impairment (WPAI).
Methods: AS patients and their treating physicians completed questionnaires capturing patient demographics, clinical status, TNFi treatment history, reasons for switching TNFi, HRQoL and WPAI. Current TNFi was determined as "failing" if, after ≥3 months, physician-rated disease severity had worsened, remained severe, was "unstable/deteriorating", physicians were dissatisfied with disease control and/or did not consider treatment a "success".
Results: The analysis included 2866 AS patients from 18 countries. Of 2795 patients with complete treatment data, 916 (32.8%) patients had never received TNFi therapy, 1623 (58.1%) patients were receiving their 1st TNFi and 200 (7.2%) patients had ever received ≥2 TNFi (treatment switch). Primary or secondary lack of efficacy were the commonest reasons for switching, and the mean delay in switching after primary lack of efficacy was 11.1 months. 232 (15.4%) patients on TNFi were currently "failing" who, compared to those with treatment success, reported poorer HRQoL: 5-dimension EuroQoL (EQ-5D-3 L): 0.63 vs. 0.78; Medical Outcomes Study Short-Form Health Survey version 2 (SF-36v2) mental component summary (MCS): 41.8 vs. 46.3; physical component summary (PCS): 40.2 vs. 45.1; impaired work productivity: 46.4% vs. 25.0%; and activity: 44.5% vs. 29.6%; all P  < 0.001.
Conclusions: Among AS patients, switching TNFi is uncommon and delayed by nearly 1 year despite primary lack of efficacy. Patients currently failing TNFi experience worse physical function, HRQoL and work productivity.
Competing Interests: Competing interestsAD has received grants or research support from AbbVie, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer and UCB Pharma, and consulting fees from Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma. VS has received grants and/or consulting fees from AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, Corrona LLC, Crescendo Bioscience, EMD Serono, F. Hoffmann-La Roche Ltd./Genentech, Inc., GSK, Janssen, Eli Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi and UCB, and has served on advisory boards for AbbVie, Amgen, AstraZeneca, BMS, Celltrion, Crescendo/Myriad Genetics, EMDSerono, Genentech/Roche, GSK, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sandoz, Sanofi and UCB. PGC has received speakers’ bureau or consulting fees from Bristol- Myers Squibb, Pfizer and Novartis. RA has received grants or research support from Bristol-Myers Squibb, consulting fees from Bristol-Myers Squibb, Novartis, Pfizer Roche and Eli Lilly. ES & SB are employees of Adelphi Real World; HT and KG are shareholders and employees of Novartis; SJ is a shareholder and employee of Novartis Pharma AG.
(© The Author(s) 2020.)
References: Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. (PMID: 31436036)
Arthritis Rheumatol. 2016 Jul;68(7):1669-76. (PMID: 26816002)
Curr Med Res Opin. 2008 Nov;24(11):3063-72. (PMID: 18826746)
N Engl J Med. 2015 Dec 24;373(26):2534-48. (PMID: 26699169)
Ann Rheum Dis. 2011 Jan;70(1):157-63. (PMID: 21062852)
Pharmacoeconomics. 1993 Nov;4(5):353-65. (PMID: 10146874)
Health Qual Life Outcomes. 2009 Mar 18;7:25. (PMID: 19296831)
Rheumatology (Oxford). 2014 Apr;53(4):650-7. (PMID: 24324212)
Rheumatology (Oxford). 2008 Jun;47(6):897-900. (PMID: 18403400)
Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. (PMID: 28235249)
Med Care. 1997 Nov;35(11):1095-108. (PMID: 9366889)
J Rheumatol. 2015 Jan;42(1):93-100. (PMID: 25362661)
Qual Life Res. 2016 Nov;25(11):2711-2723. (PMID: 27324038)
Semin Arthritis Rheum. 2017 Dec;47(3):343-350. (PMID: 28551170)
Arthritis Res Ther. 2013 Jul 26;15(4):R79. (PMID: 23890223)
Lancet. 2007 Apr 21;369(9570):1379-1390. (PMID: 17448825)
J Rheumatol. 2015 Dec;42(12):2339-46. (PMID: 26472421)
Clin Exp Rheumatol. 2011 Sep-Oct;29(5):822-7. (PMID: 22011437)
Med Care. 1992 Jun;30(6):473-83. (PMID: 1593914)
Arthritis Rheum. 2008 Feb 15;59(2):234-40. (PMID: 18240258)
Clin Exp Rheumatol. 2012 Jul-Aug;30(4):561-5. (PMID: 22510360)
Rheumatology (Oxford). 2008 Nov;47(11):1726-7. (PMID: 18782856)
Health Policy. 1990 Dec;16(3):199-208. (PMID: 10109801)
Arthritis Res Ther. 2016 Mar 22;18:71. (PMID: 27000865)
World J Orthop. 2011 Dec 18;2(12):107-15. (PMID: 22474629)
فهرسة مساهمة: Keywords: Ankylosing spondylitis; DMARD; Quality of life; Treatment failure; Tumour necrosis factor-alpha
تواريخ الأحداث: Date Created: 20200312 Latest Revision: 20220413
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7050131
DOI: 10.1186/s41927-020-0118-z
PMID: 32159075
قاعدة البيانات: MEDLINE
الوصف
تدمد:2520-1026
DOI:10.1186/s41927-020-0118-z